


Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Withdrawn) Compounds of formula I :



wherein


R^1 = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^3$, -
 $C(O)OR^3$, $-C(O)R^3$, $-CH_2C(O)OR^3$, $-CH_2C(O)NHR^3$, where R^3 is H or C_1 - C_{10} alkyl, cycloalkyl, or
alkenyl;

R^2 = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;


X^1 = NHR^4 , where R^4 is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,
the R^4 group optionally containing a carbonyl group, a carboxyl group, a carboxamide group,
an alcohol group, or an ether group, the R^4 group further optionally containing one or more
halogen atoms.

2. (Withdrawn) The compounds of claim 1, wherein R^1 is H, or C_1 - C_{10} alkyl, cycloalkyl,
alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.


3. (Withdrawn) The compounds of claim 2, wherein R^1 is $-\text{CH}_3$ or $=\text{CH}_2$.
4. (Withdrawn) The compounds of claim 3, wherein the compound is selected from the group consisting of:



5. (Withdrawn) The compounds of claim 1, wherein R^4 is $-\text{CH}_2\text{C}(\text{O})\text{OR}^5$ or $-\text{CH}_2\text{C}(\text{O})\text{NHR}^5$, where R^5 is H, $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
6. (Withdrawn) The compounds of claim 1, wherein the compound is selected from the group consisting of:



7. (Withdrawn) Compounds of formula II:



II

wherein

R^6 = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-C(O)OR^8$, $-C(O)R^8$, $-CH_2C(O)OR^8$, $-CH_2C(O)NHR^8$, where R^8 is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;

R^7 = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X^2 = NHR^9 , where R^9 is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^9 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^9 group further optionally containing one or more halogen atoms;


with the proviso that when R^6 is $-CH_3$, and R^7 is $n-C_{13}H_{27}$, X^2 is not $-NHC_2H_5$.

8. (Withdrawn) The compounds of claim 7, wherein R^6 is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

9. (Withdrawn) The compounds of claim 8, wherein R^6 is $-CH_3$.

10. (Withdrawn) The compounds of claim 7, wherein R^9 is $-CH_2C(O)OR^{10}$ or $-CH_2C(O)NHR^{10}$, where R^{10} is H, C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

11. (Withdrawn) Compounds of formula IV:



IV

wherein

$R^{16} = \text{H}$, or $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-\text{C}(\text{O})\text{OR}^{18}$, $-\text{C}(\text{O})\text{R}^{18}$, $-\text{CH}_2\text{C}(\text{O})\text{OR}^{18}$, $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{18}$, where R^{18} is H or $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl, or alkenyl;

$R^{17} = \text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;


$X^4 = \text{OR}^{19}$, where R^{19} is $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{19} group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R^{19} group further optionally containing one or more halogen atoms;

with the proviso that when R^{16} is $-\text{CH}_3$ and R^{19} is $-\text{CH}_3$, then R^{17} is not substituted or unsubstituted phenyl, $-\text{nC}_3\text{H}_7$, $-\text{nC}_5\text{H}_{11}$, $-\text{nC}_{13}\text{H}_{27}$, and with the further proviso that when R^{16} is H and R^{19} is $-\text{CH}_3$, then R^{17} is not substituted or unsubstituted phenyl or $-\text{CH}_3$, and when R^{16} is H and R^{19} is $-\text{CH}_2\text{CH}_3$, then R^{17} is not $-\text{iC}_3\text{H}_7$, or substituted or unsubstituted phenyl.

12. (Withdrawn) The compounds of claim 11, wherein R^{16} is $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13. (Withdrawn) The compounds of claim 12, wherein R^{16} is $-\text{CH}_3$.

14. (Withdrawn) The compounds of claim 11, wherein R^{19} is $-\text{CH}_2\text{C}(\text{O})\text{OR}^{20}$ or $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{20}$, where R^{20} is $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
15. (Currently Amended) Compounds of formula V:




wherein

R^{21} = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=\text{CHR}^{23}$, $-\text{C}(\text{O})\text{OR}^{23}$, $-\text{C}(\text{O})\text{R}^{23}$, $-\text{CH}_2\text{C}(\text{O})\text{OR}^{23}$, $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{23}$, where R^{23} is H or $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl, or alkenyl, except when R^{21} is $=\text{CHR}^{23}$, R^{23} is not H;

R^{22} = ~~$\text{C}_2\text{-C}_{20}$~~ $\text{C}_7\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, arylalkyl, or alkylaryl;

with the proviso that when R^{21} is $-\text{COOH}$, then R^{22} is not $-\text{CH}_3$, $-\text{nC}_5\text{H}_{11}$, or $\text{C}_{13}\text{H}_{27}$ and with the further proviso that when R^{21} is $-\text{CH}_2\text{COOH}$, then R^{22} is not $-\text{CH}_2\text{CH}_3$, or $-\text{iC}_5\text{H}_{11}$.

16. (Previously Presented) The compounds of claim 15, wherein R^{21} is cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
17. (Cancelled)
18. (Withdrawn) Compounds of formula VI:



VI

wherein:


$R^{24} = C_2-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-C(O)OR^{26}$, $-C(O)R^{26}$, $-CH_2C(O)OR^{26}$, $-CH_2C(O)NHR^{26}$, where R^{26} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

$R^{25} = C_1-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R^{24} is $-COOH$, then R^{25} is not $-CH_3$, $-nC_5H_{11}$, or $C_{13}H_{27}$, and with the further proviso that when R^{24} is $-CH_2COOH$, then R^{25} is not $-CH_3$, $-CH_2CH_3$, or $-iC_5H_{11}$.


19. (Withdrawn) The compounds of claim 18, wherein R^{21} is C_2-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20. (Previously Presented) Compounds of formula VII:




VII

wherein



21 – 22. (Cancelled)

23. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:



$R^{29} = \text{H}$, or $C_1\text{-}C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=\text{CHR}^{31}$, $-\text{C}(\text{O})\text{OR}^{31}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CH}_2\text{C}(\text{O})\text{OR}^{31}$, $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{31}$, where R^{31} is H or $C_1\text{-}C_{10}$ alkyl, cycloalkyl, or alkenyl;

$R^{30} = C_1\text{-}C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^5 = -\text{OR}^{32}$, or $-\text{NHR}^{32}$, where R^{32} is H , $C_1\text{-}C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{32} group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R^{32} group further optionally containing one or more halogen atoms;

with the proviso that when R^{29} is $=\text{CH}_2$, then X^5 is not OH .


24. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R^{29} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.

25. (Withdrawn) The pharmaceutical compositions of claim 24, wherein R^{29} is $-CH_3$ or $=CH_2$.

26. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R^{32} is $-CH_2C(O)OR^{33}$ or $-CH_2C(O)NHR^{33}$, where R^{33} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

27. (Withdrawn) The pharmaceutical compositions of claim 23, where R^{29} is $-C_6H_{13}$ or $-C_8H_{17}$.

28. (Withdrawn) The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:



29. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.

30. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.

31. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.


32. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.

33. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.

34. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.

35. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.


36. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III:




III

wherein

- $R^{11} = \text{H, or } C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, } =\text{CHR}^{13},$
- $-\text{C(O)OR}^{13}, -\text{C(O)R}^{13}, -\text{CH}_2\text{C(O)OR}^{13}, -\text{CH}_2\text{C(O)NHR}^{13},$ where R^{13} is H or $C_1\text{-}C_{10}$ alkyl, cycloalkyl, or alkenyl;
- $R^{12} = C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl ;}$
- $X^3 = \text{OR}^{14},$ where R^{14} is $C_1\text{-}C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{14} group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R^{14} group further optionally containing one or more halogen atoms.
37. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{11} is $C_1\text{-}C_{10}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=\text{CH}_2$.
38. (Withdrawn) The pharmaceutical formulation of claim 37, wherein R^{11} is $-\text{CH}_3$ or $=\text{CH}_2$.
39. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{14} is $-\text{CH}_2\text{C(O)OR}^{15}$ or $\text{CH}_2\text{C(O)NHR}^{15},$ where R^{15} is $C_1\text{-}C_{10}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
40. (Withdrawn) A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
41. (Withdrawn) The method of claim 40, wherein the subject is a human.
42. (Withdrawn) The method of claim 40, wherein the subject is an animal.
43. (Withdrawn) The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



44. (Withdrawn) The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




45. (Withdrawn) A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


46. (Withdrawn) The method of claim 45, wherein the subject is a human.

47. (Withdrawn) The method of claim 45, wherein the subject is an animal.

48. (Withdrawn) The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



49. (Withdrawn) The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




50. (Withdrawn) A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


51. (Withdrawn) The method of claim 50, wherein the subject is a human.

52. (Withdrawn) The method of claim 50, wherein the subject is an animal.


53. (Withdrawn) The method of claim 51, wherein the compound is:




54. (Withdrawn) The method of claim 52, wherein the compound is:



55. (Withdrawn) A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
56. (Withdrawn) The method of claim 55, wherein the subject is a human.
57. (Withdrawn) The method of claim 55, wherein the subject is an animal.
58. (Withdrawn) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
59. (Withdrawn) The method of claim 58, wherein the subject is a human.
60. (Withdrawn) The method of claim 58, wherein the subject is an animal.
61. (Withdrawn) The method of claim 59, wherein the compound is selected from the group consisting of:




62. (Withdrawn) The method of claim 60, wherein the compound is selected from the group consisting of:




63. (Withdrawn) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64 - 65. (Cancelled)

66. (Withdrawn) The method of claim 64, wherein the compound is selected from the group consisting of:



67. (Withdrawn) The method of claim 65, wherein the compound is selected from the group consisting of:



68. (Not Entered)

69. (Currently Amended) Compounds according to claim 15, wherein


R^{21} = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{23}$, $-C(O)OR^{23}$ $-C(O)R^{23}$, $-CH_2C(O)OR^{23}$, $-CH_2C(O)NHR^{23}$, where R^{23} is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl, except when R^{21} is $=CHR^{23}$, R^{23} is not H ;

R^{22} = C_1 - C_{20} C_7 - C_{20} alkyl, cycloalkyl, alkenyl, arylalkyl, or alkylaryl;

with the proviso that when R^{21} is $-COOH$, then R^{22} is not $-CH_3$, $-C_{13}H_{27}$ or $C_{13}H_{27}$ and with the further proviso that when R^{21} is $-CH_2COOH$, then R^{22} is not $-CH_2CH_3$, or $-iC_5H_{11}$.

70. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 69.

71. (Previously Presented) Compounds of formula X:




wherein

R^{42} = C_2 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

72. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 71.

73. (Withdrawn) A method of inhibiting the activity of fatty acid synthase in a cell comprising administering to the cell an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and one or more compounds of formula V:



wherein

R^{21} = C_2 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{23}$, $-C(O)OR^{23}$

$-C(O)R^{23}$, $-CH_2C(O)OR^{23}$, $-CH_2C(O)NHR^{23}$, where R^{23} is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl; and

R^{22} = C_2 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.